oa SA Pharmaceutical Journal - New drug focus
|Article Title||New drug focus|
|© Publisher:||Medpharm Publications|
|Journal||SA Pharmaceutical Journal|
|Publication Date||Aug 2006|
|Pages||48 - 50|
Extracted from text ... SA Pharmaceutical Journal - August 2006 48 DRUG INFO APIDRA(tm) injection - A new rapid-acting insulin analogue Approved indication APIDRA(tm) contains the insulin analogue, insulin glulisine. It is indicated for the treatment of diabetes mellitus, where insulin therapy is required. Insulin glulisine has a rapid onset of action and a shorter duration of action than human soluble insulin, when given subcutaneously. It is normally used in regimens that include a longeracting insulin or a basal insulin analogue. Mode of action Insulin glulisine is a rapid-acting, parenteral blood glucose lowering agent. Insulin glulisine is produced by recombinant DNA technology using Escherichia ..
Article metrics loading...